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Introduction: Arterial diseases including atherosclerosis, intimal hyperplasia and aneurysms have been shown to be a
product of genotype and environment. Gene expression pathways rely on protein translation to generate target effects. As
a result of alternative splicing and post-translational modifications, one gene does not code for a single protein but for
many. Proteomic studies allow quantification of these proteins in a biological system and determination of altered protein
expression in disease. Proteomics is a powerful and expanding field of investigation which in combination with other
’omics may enhance understanding of disease pathophysiology and/or identify biomarkers of vascular disease. This
review describes the methodology of protein mining and provides an insight into the valuable contributions already made
by proteomics to vascular surgery.
Methods: MEDLINE and EMBASE databases were searched for relevant articles.
Results: 118 relevant articles were identified. These were subdivided into categories based on the aspect of protein research
they reported. The subheadings include methodology, atherosclerosis, intimal hyperplasia, aortic disease and biomarkers.
Conclusions: Disease processes classified as genetic are functionally proteomic. Equally disease pathophysiology is the
result of, or leads to alternate protein expression. Understanding the proteome will clarify the pathophysiology of disease.
The translation of these findings to clinical practice impacts diagnosis, staging and treatment of disease processes.
Biomarker discovery will enable earlier diagnosis of unstable atherosclerotic plaques, it will allow identification of
aneurysms more likely to rupture and stratify risk. Proteomic research has enormous potential to modulate many aspects
of patient care. ( J Vasc Surg 2009;49:1602-12.)“Proteins are central to our understanding of cellular
function and disease processes, and without a concerted
effort in proteomics, the fruits of genomics will go unre-
alized”, Ian Humphery-Smith, co-founder of HUPO1.
The term “proteomics” was coined by Marc Wilkins in
1994. It describes the entire complement of proteins ex-
pressed by a genome, cell, tissue, or organism.2 The neol-
ogism symbolizes the association of proteomics with
genomics and transcriptionomics; and emphasizes an inte-
grated functional approach to biologic systems. Proteomics
is a rapidly growing research area, evidenced by the vast
number of publications in the field since 1996. In 1997-
1998, the search-term “proteomics” yields 22 citations in
PubMed; 1511 in 2001-2002 and 6697 in 2007-2008.
Atherosclerosis, intimal hyperplasia, and arterial aneu-
rysms are chronic inflammatory processes affecting medium
to large arteries. Understanding these disease states re-
quires clarification of changes in organ phenotype over time
to elucidate a functional disease model. The influence of
genotype and impact of environmental influences have in
part been addressed by genetic, biochemical, and systems
approaches.3 It has also become clear following the human
genome project that fewer than 30,000 genes encode for
more than a million proteins.4 Due to gene splicing and
post-translational modifications, one gene does not code
for one protein but several.
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1602Proteins are involved in every cellular function, they
control every regulatory mechanism and are, as cause or
effect, modified in disease states5 (Fig 1). Identification of
proteins active in a disease state but absent in a matched
disease-free control offers direct insight into the disease
process.6 Only through the study of proteins can the role of
a particular gene be confirmed and the function of the
protein expressed by the gene characterized. Therefore by
identifying protein modifications, proteomics enhances un-
derstanding of disease.
Mining the proteome of disease generates hypotheses
that require validation, it does not prove causality. To this
end, proteomics has been likened to a “fishing trip”, an
expensive journey of expectation unsure of what one might
catch. The technical limitations of proteomics mainly relate
to the capability of the methods to detect difficult protein
classes, like low abundance, hydrophobic and basic pro-
teins.7 Low abundance proteins might be masked by abun-
dant species eg, albumin in serum. Hydrophobic and basic
proteins have marginal solubility that can lead to precipitation
and aggregation. Reproducibility across laboratories has been
improved with mechanization of high-throughput tech-
niques, but discrimination of protein changes due to inter-
individual variation remains a challenge.8
UNDERSTANDING DISEASE STATES
The protein complement of a cell or tissue is dynamic
and reflects the age, life-cycle, and conditions the cell is
subjected to or a specific disease state. It is clear that in most
diseases, proteins are subjected to numerous changes in-
cluding post-translational modifications and/or proteo-
lytic cleavage; equally in certain diseases, there is alteration
of protein expression. Messenger RNA is the molecule
encoding the chemical blueprint for a protein. Yet the
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will not provide information on post-translational modifi-
cation, therefore the only way to assess the impact of the
proteins is at the protein level.
Proteomics as an investigative tool has proven its utility
in other fields of research including cancer and liver disease.
Its clinical role has primarily been identifying biomarkers of
disease ie, distinguishing between cancer patients and
healthy controls,9 or patients who will respond to adjuvant
treatment and those that will not.10 Proteomic investiga-
tion was adopted with great enthusiasm in fields such as
ovarian cancer, where there is no acceptable, suitable
screening test for early disease and significant mortality
remains. Despite promising early reports identifying a clus-
ter pattern of proteins with 100% sensitivity, 95% specificity
and positive predictive value of 94% in a small cohort;9
these findings have thus far failed to lead to a clinically
applicable screening tool.11 The initial proteomic fervor has
been tempered and currently we remain reliant on an older
protein biomarker, CA-125.12,13
Integration of proteomic data with other “omics” data-
sets to model cell functions at different levels will bring the
real potential of systems biology to bear on elucidating
disease processes.14 Translating these to vascular disease
may help us to identify carotid plaques and aneurysms at
risk of rupture,15 bypass grafts at risk of occlusion,16 and
methods of inhibiting aneurysm17 or atherosclerotic plaque
progression.18
PROTEOMIC METHODOLOGY
In keeping with all scientific experiments, proteomic
experiments should have clear and precise objectives at the
outset. Quantitative proteomics is the comparison of dis-
tinct proteomes (eg, control vs disease) to identify protein
species with changes in expression or post-translational
state.19 To ensure reproducibility, populations should be
age and sex matched. This may generate further hypotheses
for examination or define a biomarker for disease by con-
firming a significant fold change in single protein expres-
sion.
Serum (or plasma) proteomics. The basic elements
of “proteome mining” are sample acquisition, protein ex-
traction, protein separation, protein sequence determina-
tion and protein identification20 (Fig 2). The simplest
human product to acquire for examination of the proteome
is serum from blood. Blood is thought to contain the
majority of protein constituents found in the body.21 The
Fig 1. Key role of proteins in physiologic pathway.ease of acquisition sadly does not correspond to ease ofinterrogation. The dynamic range of proteins in serum
makes analysis very challenging because high abundance
proteins tend to mask those of lower abundance;22 whilst a
small number of proteins including albumin, 2-macro-
globulin, transferrin, and immunoglobulins may represent
over 90% of serum proteins.
Samples. Blood is a popular source for biologic sam-
ples for proteomic analysis. Serum or plasma from these
samples can be analyzed. Serum is qualitatively different
from plasma as the bulk of the fibrinogen and platelets have
been removed by formation of the fibrin clot.23 This differ-
entiation is important as proteins involved in clot formation
are frequently associated with disease, eg, fibrinogen
changes in acute coronary syndrome.24 Plasma represents
the parent mixture of proteins, and keen to avoid in vitro
proteolysis as part of the sample acquisition protocol, re-
mains the preferred fluid sample for analysis.25
Techniques of depletion of these multiple high abun-
dance proteins, including Multiple Affinity Removal Sys-
tems MARS columns (MARS)26 and heparin chromatog-
raphy27 have been shown to improve protein profiling
capacity in human serum. The key shortcomings of this
method are that proteins of interest may be removed along
with the targeted protein, and albumin may act as a carrier
or molecular sponge that binds other potentially important
proteins or peptides. Pooling of serum samples will increase
the chance of detection of low abundance proteins; how-
ever, findings, certainly in the case of biomarkers of disease,
need validation on an individual-to-individual basis.28 Even
Fig 2. Two-dimensional gel protein processing.if it were possible to remove 99.9% of albumin,5 g/mL
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dance proteins present in concentrations of 5 pg/mL.25
Yield can be enhanced by protein enrichment. Tech-
niques include immunoprecipitation and immuno-affinity
chromatography.29 These techniques lack the power of
polymerase chain reaction (PCR) in genomics. PCR allows
exponential amplification of DNA from a single or few
copies. Protein expression cannot be amplified; the re-
searcher is limited to the volume of protein extracted from
the tissue or blood sample. The enrichment tools are,
however, robust and selective aids to biomarker research.
Tissue proteomics. Less readily accessible, but prob-
ably more fruitful is specific organ tissue for proteomic
analysis. At the research level, this obviates the challenges of
plasma proteins whilst snap freezing following harvest will
inhibit protease activity. Transferability of this tool into
clinical practice is obviously limited relative to plasma but
could be equivalent to a diagnostic biopsy.
Two-dimensional gel electrophoresis. The most
widely used tool for proteomic analysis is two-dimensional
(2D) gel electrophoresis (2DE). This resolves complex
mixtures of proteins first by isoelectric point (pI), then by
relative molecular mass (Mr). To compare proteins from
different samples a modification of 2DE called difference in
gel electrophoresis (DIGE) is used. Protein samples are
labeled with one of three primary colored dyes prior to
separation; three samples are then mixed and resolved on
the same 2D gel. A pooled “internal standard” allows for
confident gel-to-gel comparison.20 Data is acquired by
laser densitometry of gel spots, and results are processed by
software packages to identify spots that are qualitatively
different or that are up- or downregulated.
The identity of protein spots of interest are character-
ized by mass spectrometry (MS). Protein spots are excised
from the gels and digested with trypsin to cleave the pro-
teins at specific amino acid sequences (if present), breaking
its primary structure into constituent peptide fragments.
The peptides are ionized and separated by mass-to-charge
ratio using a mass spectrometer. The protein is identified
according to its mass fingerprint.30
Experiments performed in the laboratory are comple-
mented by virtual experiments performed on the computer.
Bioinformatic tools are available allowing protein identifi-
cation and have the power to further characterize the
proteins from calculation of basic physicochemical proper-
ties.31
Shotgun proteomics. The key flaws of 2-D gel anal-
ysis are its bias towards highly abundant proteins and its
labor intensive, nonautomated approach.32 “Shotgun pro-
teomics” is a protein identification technique combining
high performance liquid chromatography with mass spec-
trometry. This bottom-up technique involves the biologic
sample being digested prior to separation and analysis
allowing high throughput peptide analysis. The challenge
of interpreting this data lies in assigning identified peptides
to the proteins from which they originated.33 Specific
algorithms for matching the mass spectra data, based on the
knowledge of the genome and rules of peptide fragmenta-tion, are relied upon to define the protein expression.34
Isotope coded affinity tagging (ICAT) and isobaric tag for
relative and absolute quantitation (iTRAQ) (Fig 3) allow
protein quantification using a shotgun approach.
Individually, there are pros and cons to each technique.
DIGE can be performed in smaller laboratories without
mechanization; however, comigration of proteins can com-
promise accuracy. ICAT is as sensitive as DIGE, but be-
cause of the labels binding on the cysteine residues, it can
be biased towards these proteins. ITRAQ is the most
sensitive proteomic tool, yet it is more susceptible to errors
with increased sample complexity. Each of these three
systems, DIGE, ICAT, and iTRAQ yield good results with
moderate complexity samples and can be complementary in
providing a better portrait of the proteome.35
As the field of proteomics has expanded rapidly, there
have been efforts to refine the quality and validity of re-
ported findings. Reporting standards, endorsed by HUPO,
for the journal “Proteomics” have been put in place to
reflect the desirable minimal characteristics of robust re-
search in this field.36 These include appropriate experiment
design, techniques of protein characterization, and disclo-
sure of raw expression data.
RELEVANCE TO VASCULAR DISEASES
A consistent factor in vascular pathologies is modula-
Fig 3. Comparative methodology of three proteomic tech-
niques.tion of the smooth muscle cell phenotype within the vas-
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and are capable of switching easily from a contractile state
to an activated synthetic phenotype. This plasticity is the
basis of the vascular smooth muscle cell (VSMC) migration
and proliferation involved in the formation of atheroma
and intimal hyperplasia in the arterial wall.37
Genetic studies have provided insight into the process
and regulation of VSMC phenotypic modulation.38 How-
ever, few studies have correlated genomic sequence or
transcription profile with protein activation. The impor-
tance of understanding the functional proteins in the
proteome is becoming clearer; certainly the modified
functional proteins in disease. Boccardi et al conducted
proteomic analysis of protein changes facilitating the switch
from quiescent VSMC to an active-proliferating pheno-
type. This comparison discovered 105 proteins that were
upregulated and 154 that were downregulated in activated
cells relative to the quiescent “contractile” phenotype.
They identified proteins involved in redox regulation, cy-
toskeletal proteins, and enzymes of glucose metabolism.37
They provided clues regarding the early events involved in
cell activation which may identify triggers controlling
VSMC remodeling.6
ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory disease char-
acterized by endothelial activation, cellular influx, and pro-
duction of mediators and cytokines.39 Efforts to under-
stand the mechanism and identify biomarkers of the disease
process have indicated that many proteins are involved in
the disease.40 The step-wise pathogenesis that leads to
plaque rupture involves key intracellular and extracellular
protein signaling mechanisms. The integral role of the
VSMC is a focal point of investigation.
Databases of protein expression maps in normal physi-
ologic conditions have been produced. Two-dimensional
electrophoresis has been used to map the VSMC in human
great saphenous vein16 and internal mammary artery.41
One hundred twenty-nine proteins were mapped in the
saphenous vein medial smooth muscle, the first step in
elucidating the molecular events involved in saphenous
vein bypass graft failure. The primary culture of VSMCs
from internal mammary artery identified 83 intracellular
and 18 secreted different proteins. These findings clarify
understanding of normal regulation of VSMC differentia-
tion, the next step is comparison of protein expression in
health and disease.
Serum studies. Serum has been used to assess protein
expression in atherosclerotic myocardial ischemia. A small
Spanish study comparing patients with acute coronary syn-
drome (ACS) with matched controls found altered expres-
sion of five plasma proteins. These included alpha-1-
antitrypsin, immunoglobulin-, apolipoprotein-a-1, and
fibrinogen- chain; all normal constituents of plasma.24 This
pilot study was superseded by a larger study, using shotgun
proteomics, reported by Donahue et al with 53 patients,
and a similar number of matched controls. Plasma samples
were pooled, enriched by albumin depletion, and withtandem-mass spectrometry, 95 differentially expressed pro-
teins were identified. These proteins covered broad catego-
ries involved in diverse applications of inflammation,
growth coagulation and natural defenses.42 However,
these two human plasma proteomic studies have their
design flaws. The latter study utilized pooled sampling.
This may increase the likelihood of identifying low abun-
dance proteins, but any finding requires further validation
to confirm significance. The patient population was “elec-
tive”, without acute pathology. Although atherosclerosis is
a chronic disease, there will be fluctuation of the dynamic
proteome dependent on disease activity.
The time-dependent protein abundance in plasma has
been examined by utilizing a mouse model of atheroscle-
rosis. A longitudinal study of serum protein expression
revealed 22 markers demonstrating unique time-related
patterns of expression, some of which correlated closely
with the extent of atherosclerotic lesions in the mice aortas.
The top serum protein classifiers identified encompassed a
wide range of atherosclerotic biologic processes including
macrophage chemo-attraction (Ccl2, Ccl9), T-cell chemo-
kine activity (Ccl19, Ccl21), innate immunity (Il5), vascular
calcification (Tnfsf11), and vasculogenesis (vegfa).43
Tissue studies. The earliest tissue study of pathologic
protein expression in vivo, reported by Stastny et al, used
2D electrophoresis to compare protein expression in fibro-
fatty and lesion free aortic intima. In the small cohort of
young patients, they identified upregulation of plasma
proteins albumin, alpha-1-antitrypsin, transferrin, and
Apo-A-I.44 These early 2D gels lacked the specificity of
modern systems.
When carotid arterial plaques were compared with
healthy internal mammary artery, seven proteins with a
greater than fivefold expression change were discovered.
The most apparent change was the downregulation of
apoptosis-linked gene 2 protein (APG-2), a positive medi-
ator of apoptotic cell death. Martinet et al concluded that
this finding pointed towards a novel survival mechanism
against cell death in human atherosclerotic plaques.45 Ath-
erosclerotic aortic plaques from patients requiring aortic
bypass procedures were analyzed by Sung et al.46 They
identified 27 differentially expressed proteins in atheroscle-
rotic disease with roles in VSMC migration, matrix metallo-
proteinase (MMP) activation, and regulation of proinflamma-
tory cytokines. These findings reinforced the evidence for the
role of MMPs in atherosclerosis.
Plaque rupture is the predominant cause of ACS and
peripheral vascular disease.47 The symptoms of carotid
artery atherosclerosis follow conversion of stable plaques to
unstable ones. Protein deregulation is associated with un-
stable carotid plaque regions. Proapoptotic and DNA re-
pair proteins are all overexpressed in endothelial and
smooth muscle cells of unstable regions of atherosclerotic
plaque. These could be sites of therapeutic modulation to
stabilize rupture prone plaques.48
Cell culture studies. Proteomic analysis of the cul-
tured VSMC proteome and proteins of its secretome has
been performed. Theoretically, this might provide a clearer
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sic to the VSMC. However, cultured cells may only reflect
the intrinsic pathologic potential of cells, rather than the
original proteome expression within the arterial wall before
culture induced phenotype adaptation.
In normal physiologic conditions, the expression of 18
reproducible proteins the secretome of the human VSMC
have been identified.41 The other key cell described in
atherogenesis is the macrophage. A total of 38 different
proteins have been identified in the secretome of the nor-
mal marcophage.49
Differential protein expressions of cells at alternate sites
of the atherosclerotic plaque have been reported. Compar-
ing normal carotid artery, noncomplicated plaque and
plaque complicated by thrombus the secretome has shown
to markedly vary in protein expression. Two-dimensional
gel electrophoresis of each sample’s secretome showed 52,
154, and 202 proteins, respectively. The more complex the
lesion, the larger variety of secreted proteins. This suggests
that specific proteins are produced relative to the complex-
ity of the lesion.50 Combining these findings, there does
appear to be unique protein expression in the pathologic
secretome, whether this reflects cause or effect remains
unclear.
Specific protein changes within the cultured atheroscle-
rotic vessel secretome include HSP27 suppression.51 This
finding has shown clinical translation where circulating
HSP27 levels are significantly decreased in the blood of
patients with carotid stenosis relative to healthy subjects
(0.19 vs 83 ng/mL, P .0001). This may reflect a first step
towards a positive biomarker for atherosclerosis although
validation in broader cohorts is required.
Animal study. Proteomic research has also been ap-
plied to understanding the pharmacologic interactions with
plaques. VSMC proliferation and migration is integral to
intimal hyperplasia after lesion angioplasty. Rapamycin an
inhibitor of cell proliferation, was found to suppress SMC
extracellular matrix protein production in a dose dependent
manner after local vascular injury in an animal model.52
INTIMAL HYPERPLASIA
Intimal hyperplasia (IH), a fibroproliferative lesion
characterized by intimal thickening, is the predominant
cause of bypass graft occlusions in the first 2 years after
implantation.53,54 The thickened intima consists primarily
of VSMCs bearing a proliferative, synthetic, and dediffer-
entiated phenotype.55
Once in situ as an arterial conduit; the vein graft under-
goes arterialization. This remodeling involves three key
changes: medial fibrous replacement, adventitial fibrous
proliferation, and intimal fibrous proliferation. These
changes cannot be explained simply be elevation in pres-
sure. The extracellular matrix proteins play a crucial role in
blood vessel remodeling by affecting cell adhesion, growth,
migration, adaptation and morphology.56
Tissue studies. The early changes in contractile prop-
erties of vein exposed to arterial hemodynamics include
sensitization to vasoconstrictors and increased force gener-ation via Rho-kinase signaling.57 McGregor et al studied
the proteomic changes expressed by the venous SMC fol-
lowing arterialization. They utilized harvested human sa-
phenous vein and examined the protein expression changes
when the vein was subjected to simulated arterial flow in
vitro. They reported a 1.6-fold increase in HSP27 expres-
sion (P  .01), 90 minutes following arterialization and a
threefold decrease in abundance of actin-capping protein
CapZ (P  .04).58 The significance of these findings may
be linked to their role on actin filaments influencing the
force generation of vascular smooth muscle.59
Animal studies. The majority of vein graft neointimal
and medial cells derive from precursors extrinsic to the vein
at the time of grafting.60 The role of survivin, an inhibitor
of apoptosis protein has been challenged initially for ge-
netic expression61 and latterly for expression in the pro-
teome.62 Survivin appears to regulate proliferation as well
as apoptosis in VSMCs. It is a critical regulator of VSMC
apoptosis and proliferation and is an integral determinant
of the remodeling response of vein grafts following arteri-
alization. Survivin is virtually undetectable in normal arter-
ies and veins in humans and animal models. However,
following local trauma or vein grafting, striking upregula-
tion of survivin expression occurs.
RNA analysis of artery and vein grafts from an animal
model has confirmed that survivin upregulation occurs at
the transcription level, it begins several days to a week
following vascular injury and remains elevated up to 3
months later.63 Inhibition of survivin expression results in a
63% reduction in neo-intimal formation and correlates
directly with an increase in apoptotic cells in vessel walls.64
Survivin plays an important role in early remodeling of
arterialized veins, and it has been suggested that acute
intervention targeting this pathway may substantially alter
the long-term healing response.55
Heat shock proteins (HSP) prevent intimal hyperplasia
in an animal model of angioplasty. Herbimycin A, a phar-
macologic heat shock protein inducer, significantly attenu-
ates intimal hyperplasia after balloon injury.65 These results
suggest that HSP27 mediates the response and inducers of
HSP27 may have a therapeutic role in prevention of intimal
hyperplasia. In normal physiology. heat shock proteins are
important in the build up of tolerance and cytoprotection
against stresses such as ischemia, hypoxia, and exposure to
xenobiotics.66
AORTIC DISEASE
The application of proteomics to aortic aneurismal
disease may further understanding of the pathophysiology
of the disease. The determination of biomarkers that can
predict aneurysm development, risk of aneurysm rupture,
and the patients’ perioperative risk are all areas where
proteomics has been and is currently being applied. Signif-
icant morbidity and mortality still surrounds aortic surgery,
which on the whole is risk reduction to prevent aneurysm
rupture. The indication for elective surgery is an aorta5.5
cm diameter, yet approximately half the large aneurysms
operated on would not proceed to rupture.67 A serum
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erful tool to stratify patients with small screen detected
aneurysms.
Aortic aneurysms occur as a result of a number of
pathologic steps. Smooth muscle cell apoptosis, extracellu-
lar matrix degradation by proteases, adventitial angiogene-
sis, and mural thrombus all contribute to the aneurismal
phenotype. The significant role of matrix metallopro-
teinases in aneurysm pathogenesis has been thoroughly
reported.68,69
Tissue studies. Total HSP27 and phosphorylated
HSP27 are decreased in arterial plaques compared to nor-
mal aorta.70 The decrease in HSP27s may reflect the in-
creased level of proteases known to degrade them. Down-
regulation of HSP27 has been shown to increase the rate of
smooth muscle cell apoptosis and subsequently lead to
higher levels of MMP-2.71 The protein-protease relation-
ship in disease is unlikely to be linear but HSP27 appears to
have significant interplay with proteases implicit in aneu-
rysm etiology.
Six differentially expressed protein spots have been
identified in the abdominal aortic aneurysm (AAA) wall
that correlate with aneurysm size and 16 that correlate with
AAA expansion rate. These findings may be the early steps
towards potential biomarkers for growth.72 The same
group compared protein expression in ruptured and non-
ruptured AAA tissue. This comparative study demonstrated
seven differentially expressed proteins, concluding that
rupture was a consequence of response to a stressful condi-
tion and resulted from proteolytic degradation of the aortic
cytoskeleton.73 Human tissue analysis of the aneurismal
proteome is hampered by both appropriate control tissue
and the inability to biopsy aneurysm tissue through its
development.
Aortic dissection is characterized by separation of the
vessel wall layers by extra luminal blood, often via an intimal
tear. Mechanisms weakening the aortic wall can induce
aortic dilatation, aneurysm formation, and even rupture.
Protein expression has been compared between aortas re-
quiring surgery for dissection and normal cadaveric con-
trols, with 26 differentially expressed proteins identified,
which may have contributed to the pathogenesis. These
included cytoskeletal proteins; smooth muscle-22-,
destrin and -actin. Decreased expression of HSP27, os-
teoglycin (an essential component of normal vascular ma-
trix) and EC-SOD (extracellular superoxide dismutase) was
found in the dissection cohort. These findings highlight the
role of oxidative stress in aortic wall weakness.74 EC-SOD
is part of the enzymatic antioxidant defense system and
HSP27 has been proposed to increase the resistance against
oxidative stress-induced actin fragmentation.58 The de-
creased osteoglycin expression in dissection suggests
VSMC phenotype change and that vascular matrix remod-
eling may occur in this pathology.
Cell culture studies. Smoking has been irrefutably
associated with AAA and atherosclerosis (7.6 relative
risk).75 The effect of cigarette smoke extracts on aortic
endothelial cells’ protein expression has been analyzed invitro. Sixteen proteins exhibit altered expression after ex-
posure to cigarette smoke extract. Increased expression of
HSP27, HSP70, and gp96 was reported. Interestingly,
although the expression of these “protective” proteins was
increased eightfold, that in isolation, this was not enough
to prevent the endothelial cells from dying. Among the
downregulated proteins was -tubulin, a monomer, which
combines to form microtubules, complexes essential to cell
function. Degradation of microtubules is a hallmark of
apoptosis.76
BIOMARKERS OF VASCULAR DISEASE
Biomarkers are usually disease-associated proteins that
can be detected and quantitatively measured for disease
diagnosis, staging, prognosis, and treatment monitoring.
They allow stratification of risk, assessment of disease states,
or act as surrogate endpoints for response to treatment.
The key applications in vascular disease are in identification
of high risk patients for plaque rupture, aneurysm growth
and rupture, or early cardiomyopathy. Table I presents
some key examples of biomarkers correlated to vascular
disease.
Biomarkers must be measurable, add new information
and aid the clinicians’ management of patients.77 To apply
the biomarker to a risk prediction model, it must allow
discrimination, calibration, and risk stratification. Table II
demonstrates the step-wise path to biomarker discovery.
The five phases (P1-P5) reflect the requisite steps to imple-
mentation of a disease biomarker. Discrimination is the
specificity and sensitivity of the marker, calibration denotes
the ability of the marker to assign predicted risks that match
actual observed risk and risk stratification is the power to
assign patients into clinically relevant categories.
A classical example. Troponin is an established clini-
cal biomarker of myocardial infarction (MI). The diagnosis
of MI is supported by a convincing history, electrocardio-
gram changes, and the detection of a protein biomarker for
myocardial necrosis. The biomarker is a result of the sys-
temic spillover of structural, myocardial specific myofila-
ment proteins (troponins).78 The levels of protein, due to
the time course and extent of systemic release, correlate
well with MI. First discovered by Ebashi in 1963,79 tropo-
nin’s utility as a biomarker was highlighted in 1989 when a
standardized immunoassay for circulating troponin T was
developed.80 It underwent clinical validation against the
then best marker of MI, CK-MB, and was found to improve
the efficiency of diagnosis of myocardial cell necrosis.81 In
2000, the American Heart association incorporated a pos-
itive troponin T rise into its definition of myocardial infarc-
tion,82 and it remains the gold standard for the diagnosis of
cardiac ischemia.83
AAA biomarkers. Aortic aneurysm diameter is the
major predictor of aneurysm rupture. Rupture risk in-
creases when growth exceeds the expected expansion
rate.67 Studies continue to identify a biomarker that could
predict rupture. To date serum elastin peptide (SEP) ap-
pears to be the best quality biomarker for aortic growth
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limits its clinical translation.
In the modern “endovascular era”, biomarkers of an-
eurysm progression would have utility following aneurysm
exclusion by endovascular aneurysm repair (EVAR). A sim-
ple blood marker of growth could become integral to graft
follow-up and minimize the radiologic exposure.85
Serum tissue plasminogen activator (tPA) has been
Table I. Examples of proteomic biomarkers of vascular di
Author
AAA (expansion)
Osteoprotegerin Moran103
Tissue-type plasminogen activator (t-Pa) Lindholt104
Cystatin-C Lindholt105
Macrophage migratory inhibitory factor (MIF) Pan106
P-plasmin-antiplasmin complexes Lindholt107
MMP-9 Lindholt108
AAA (rupture)
Serum elastin peptides (SEP) Lindholt84
Aminoterminal propeptide of type III
procollagen
Satta109
Atherosclerotic plaque (progression)
Oxidized-LDL Salonen110
Atherosclerotic plaque (rupture)
Cathepsin B Chen111
hsCRP Burke112
IL-18 Mallat113
IL- 6 Maier114
Pregnancy associated plasma protein-A
(PAPP-A)
Sangiorgi115
Peripheral vascular disease (diagnostic markers)
Soluble intercellular adhesion molecule-1 Pradhan116

-2 microglobulin Wilson117

-2 microglobulin  cystatin C  hsCRP 
glucose
Fung118
AAA, Abdominal aortic aneurysm; MMP, matrix metalloproteinase.
Table II. Translating biomarker discovery from the
laboratory to patients
Phase Title Explanation
P1 Discovery Exploratory studies to identify
potential biomarkers
P2 Validation Capacity of biomarker to discriminate
between health and disease
P3 Preclinical Capacity of biomarker to detect pre-
clinical disease
P4 Prospective Prospective screening studies for
sensitivity of biomarker
P5 Impact Large scale study to asses impact of
biomarker on survivalreported to show predictive power for aneurysms to expandto a size indicating surgical intervention with an optimal
specificity and sensitivity of 0.73 and 0.71, respectively
(P  .015). It has been proposed that this finding is
reflective of the association of aortic expansion with smok-
ing. In that study smoking and tPA were found on the same
line of causality.85
Unstable plaques. Atherosclerotic plaque rupture
leads to stroke and MI. A biomarker to discriminate be-
tween patients with high and low risk plaques would allow
targeted therapy to patients with high risk plaques. C
reactive protein (CRP) has been assessed in an abundance
of studies, probably due to the American Heart Association
(AHA) scientific statement limiting the use of inflammatory
markers in disease states to those with commercially avail-
able, standardized, and precise assays.86 Meta-analysis of 14
of these papers with long-term prospective data has dem-
onstrated a summary relative risk for coronary heart disease
of 1.9 (95% CI 1.5-2.3) for the top vs the bottom tertile for
CRP distribution.87 CRP lacks the sensitivity to become a
population screening tool.
The Health ABC study investigated the predictive value
of inflammatory markers (CRP, IL-6, TNF-) in cardiovascu-
r Significance
5 Plasma level correlation with growth (r  0.2), Tissue levels
12 increased expression vs. controls
3 Plasma level correlation with growth (r  0.37)
1 Negative correlation with expansion rate (r  	0.24)
3 Serum MIF correlated with expansion rate (r  0.28)
1 Plasma level correlation with growth (r  0.39)
0 Elevated in aneurismal aortic walls – correlates with
expansion of small AAAs (r  0.33)
1 SEP levels higher in cases prone to rupture relative to
controls (60% specificity) (r  0.40)
7 Acceleration of AAA growth is reflected in serum PIIINP
(r  0.55, P  .002)
7 Titre of autoantibodies to MDA-modified LDL
independently predicts progression of carotid
atherosclerosis
2 Potential biomarker for vulnerable plaques
2 Elevated levels in plaques prone to rupture (mean log
hsCRP higher in rupture vs control (P  .0001)
1 Expression increased in unstable atherosclerotic plaque vs
control
5 IL-6 expression increased at site of plaque rupture vs
systemic circulation - No systemic value
6 Abundantly expressed in eroded/ruptured carotid plaques
(4 increase) vs stable plaques
8 sICAM-1 is a potent predictor of PVD (Hazard ratio 3.5)
7 
-2 Microglobulin levels had an inverse correlation with
ABPI (r  	0.727, P  .001)
8 “Biomarker panel” demonstrated association with PVD
(OR 7.3)sease
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200
200
200
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199
200
200
200
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200lar events in well functioning elder people. They identified
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predictions, if a patient recorded all three markers in the upper
tertile coronary heart disease relative risk was 2.1 (95% CI
1.2-3.5). IL-6 was the only marker predictive of stroke where
being in the upper tertile reflected a relative risk of 3.70 (95%
CI 1.6-8.2).88
Risk stratification. Proteomics has been applied to
evaluation of risk at surgery. The association of pre- and
perioperative protein expression on postoperative multior-
gan dysfunction (MODS) was examined. Differential pro-
tein expression was observed in patients who went on to
develop MODS and those who did not. Specifically IFN-
-inducible protein-10 (IF-10) level was a statistically sig-
nificant pre-clamp marker for subsequent MODS (3.9-fold
in MODS patients, P-B  .1).89 Protein biomarkers may
contribute to preoperative risk calculation alongside phys-
iologic variables. Contemporary biomarkers only add mod-
erately to standard risk factor assessment.90
OTHER APPLICATIONS
Estrogen and vascular disease. Proteomics has been
used to assess the protective effects of estrogens on the
cardiovascular system. Two-dimensional gel electrophore-
sis of the secretome of cultured bovine aortic smooth
muscle cells incubated with and without 17
-oestradiol has
demonstrated clear differential protein expression. All iden-
tified proteins were integral in SMC proliferation confirm-
ing that 17
-oestradiol modulates a wide range of signaling
pathways in SMCs.91
Diabetes. Diabetes influences many vascular disease
processes, being a risk factor for atherosclerosis92 and pro-
tective for aneurismal disease.93,94 Type 1 diabetes is the
result of selective destruction of the insulin-producing

-cells in the pancreatic islets of Langerhans. Genetic stud-
ies have failed to identify pathways modulating pro-
grammed cell death. Proteomics may be useful in describ-
ing the protein expression profile and thus the diabetic
phenotype.95 The organ specific nature of diabetes should
make it ideal for proteomic analysis. Yet, the majority of
research has been limited to animal models. The human
pancreatic proteome has been described and may provide a
reference for interpretation of pancreatic pathology.96
One of the mechanisms of development of type 1
diabetes, in genetically predisposed individuals, is via toxic
cytokine release from macrophages. Proteomic techniques
have been applied to rat islet cells exposed to the cytokine
interleukin-1 (IL-1)
. Over 100 differentially expressed
proteins were identified, yet the functional significance in
humans is unclear.97
Serum proteomic studies have as yet failed to identify
any biomarkers for early diabetes.98 Although a candidate
study has reported differential protein expression in type 2
diabetes vs controls. The potential for this technology
remains untapped.21
CLINICAL TRANSLATION AND THE FUTURE
An alternative perspective is that disease processes clas-
sified as genetic are functionally proteomic.3 The geneticmutations modify the protein signaling pathway, altering
the proteomic tissue microenvironment and perpetuating
disease.99 Unfortunately, in many cases, a stroke from an
unstable carotid plaque and rupture from an aortic aneu-
rysm are diagnosed too late. Optimal surgical outcome is
provided by prophylactic intervention in both cases, and
the key step is to differentiate those patients that will benefit
most from interventions – through biomarker technology.
The expectation of identification of a single biomarker
for these diseases may be unrealistic. The future probably
lies in discovering a “molecular signature” of disease, com-
bining biomarkers to allocate risk, similar to the clinical
Framingham risk model.100 Proteomic discoveries and
their application to clinical practice will have a substantial
impact on future patient care.
There are ongoing major projects using proteomic
techniques to further clarify the pathophysiology of aneu-
rismal disease. The “Fighting Aneurismal Disease” project
started in July 2008, with a remit of coordinating research
in genetics, proteomics, pathophysiology and therapeutics
of aneurismal disease across Europe.101 On a larger scale,
the Human Proteome Organization (HUPO) have plans
for an ambitious project to map the entire human pro-
teome.102
Proteomic discoveries can be combined with knowl-
edge from molecular biology to attempt to model global
cell networks. The limitation of this lies in it providing a
snap-shot of cell activity at a time period. Cells are in a
constant state of change. Models of dynamic cell activity are
not yet available, current knowledge is based on prediction.
CONCLUSION
The findings of this review demonstrate the diverse
range of proteins implicated by proteomic studies in vascu-
lar pathology. Knowledge of vascular pathology and further
understanding of mechanism of disease has been enhanced
by proteomic research. Alongside other biologic research
techniques, proteomics is another powerful tool in the
scientists’ armamentarium.
One essential question that remains unanswered is
whether the differential protein expression in disease is caus-
ative or secondary to the pathology. Although this is not
relevant when attributing a biomarker to disease, when look-
ing to interrupt or inhibit disease progression full understand-
ing of the proteome is necessary. This will develop with further
human tissue proteomic exploration aided by consistent re-
producible automated processing.
Proteomics certainly has much more to offer the field of
vascular surgery, where in 10 years time, the decision to
operate on a dilated aorta or carotid stenosis may be guided
by the presence of a protein in the patient’s serum, or local
delivery of patient specific protein modulation may be the
optimal therapy.
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